Malignant Bladder Neoplasm

cancer

Identifier: CI-CAN-00005866
Entity page: /cancer/malignant-bladder-neoplasm ↗
Edges: 2,077

Neighbours: 16 genes2 variants19 drugs10 trials
Drawn: 47 of 47 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Bladder Neoplasm approved for …APPROVED_FOR13 of 7
← approved for	Pembrolizumabmonoclonal_antibody	supports	FDA ORIG	Malignant Bladder Neoplasm	1	Regulatory	openfda	graph →
← approved for	Enfortumab Vedotinadc	supports	FDA ORIG

Malignant Bladder Neoplasm predicts response to …PREDICTS_RESPONSE_TO3 of 3
in context · predicts response to	FGFR3 Mutationother → predicts response to Gemcitabine	sensitivity	B	Malignant Bladder Neoplasm	1	Curated	civic	graph →
in context · predicts response to	FGFR3 Mutationother → predicts response to Cisplatin	sensitivity	B	Malignant Bladder Neoplasm	1	Curated	civic	graph →
in context · predicts response to	FGFR3 S249CSNV → predicts response to Erdafitinib	sensitivity	D	Malignant Bladder Neoplasm	1	Curated	civic	graph →

Malignant Bladder Neoplasm predicts response to …PREDICTS_RESPONSE_TO3 of 3

in context · predicts response to

FGFR3 Mutationother → predicts response to Gemcitabine

sensitivity

Malignant Bladder Neoplasm

Curated

Malignant Bladder Neoplasm associated with …ASSOCIATED_WITH3 of 3
← associated with	FGFR3	supports	B	Malignant Bladder Neoplasm	1	Curated	civic	graph →
← associated with	FGFR3	supports	C	Malignant Bladder Neoplasm	1	Curated	civic	graph →
← associated with	FGFR3 3 source records aggregated	supports	D	Malignant Bladder Neoplasm	3	Curated	civic	graph →

Malignant Bladder Neoplasm investigated for …INVESTIGATED_FOR3 of 3
← investigated for	Gemcitabinesmall_molecule	supports	B	Malignant Bladder Neoplasm	1	Curated	civic	graph →
← investigated for	Cisplatinsmall_molecule	supports	B	Malignant Bladder Neoplasm	1	Curated	civic	graph →
← investigated for	Erdafitinibsmall_molecule	supports	D	Malignant Bladder Neoplasm	1	Curated	civic	graph →

Malignant Bladder Neoplasm altered in cohorts of …ALTERED_INderived15 of 408show all (up to 200)
← altered in cohorts of	CDH1 27 / 34 cases (79 %) · ssm · blca_plasmacytoid_mskcc_2016	—	—	Bladder Urothelial Carcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CDKN2B 267 / 412 cases (65 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MTAP 261 / 412 cases (63 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	UBR5 259 / 412 cases (63 %) · ssm · TCGA-BLCA · largest of 4 cohorts	—	—	Bladder Urothelial Carcinoma	4	Observed	gdc	graph →
← altered in cohorts of	DMRTA1 255 / 412 cases (62 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	GRHL2 255 / 412 cases (62 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 253 / 412 cases (61 %) · ssm · TCGA-BLCA · largest of 4 cohorts	—	—	Bladder Urothelial Carcinoma	4	Observed	gdc	graph →
← altered in cohorts of	MYOM2 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PABPC1 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TEX15 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TNFRSF10A 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ZNF706 253 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ADRA1A 252 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	RIMS2 252 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDCA2 251 / 412 cases (61 %) · ssm · TCGA-BLCA	—	—	Bladder Urothelial Carcinoma	1	Observed	gdc	graph →

Malignant Bladder Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 143show all (up to 200)
→ investigated in trials for	Gemcitabinesmall_molecule 126 trials (39 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	126	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 94 trials (27 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	94	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 65 trials (36 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 38 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Mitomycinsmall molecule 36 trials (16 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 32 trials (8 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 30 trials (15 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 27 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal_antibody 25 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal_antibody 25 trials (12 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Enfortumab Vedotinadc 24 trials (20 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 22 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 18 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Vinblastinesmall molecule 17 trials (2 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 16 trials (9 active) · roll-up of the cancer and its descendants	—	—	Malignant Bladder Neoplasm	16	Observed	clinicaltrials	graph →

Malignant Bladder Neoplasm studied in …STUDIED_INderived10 of 1,510show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,510 trials mapped (472 active)	—	—	Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04502095Phase 4 · completed Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy · condition mapped ONTOLOGY_EXACT · 1,510 trials mapped (472 active)	—	—	Bladder Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped CURATED_EXACT · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 1,510 trials mapped (472 active)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061964Phase 2 · recruiting Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial · condition mapped CURATED_BROADER · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04235764recruiting En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device · condition mapped CURATED_EXACT · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04235777Phase 1 · active not recruiting Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies · condition mapped CURATED_EXACT · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06331299Phase 3 · active not recruiting A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer · condition mapped CURATED_EXACT · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · condition mapped CURATED_BROADER · 1,510 trials mapped (472 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains